Related Experiment Video
Updated: Feb 17, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Advances in targeting HER2-positive breast cancer
1Breast Center, Department of OB&GYN, University of Munich (LMU) Munich, Germany.
Purpose Of Review:
Breast cancer is the most common malignancy in women and HER2-positive disease comprises about 15% of all breast cancer cases. Over the last few years, substantial advances have been made in treatment of early breast cancer (EBC) and advanced (ABC) HER2-positive (HER2+) breast cancer. The present review summarizes the major publications on HER2+ breast cancer in the year 2017 and discusses their clinical relevance.
Recent Findings:
The clinically most relevant data in 2017 relates to the EBC setting. The St. Gallen Consensus 2017 for the first time recommended neoadjuvant treatment as standard of care in HER2+ EBC. Moreover, the APHINITY trial demonstrated efficacy of adjuvant dual antibody-based HER2 blockade. Data in MBC mostly confirmed established treatment strategies.
Summary:
Clinical data presented in 2017 for HER2+ breast cancer confirmed current guidelines and extended treatment options for patients. First intriguing steps were made towards de-escalation in the EBC setting.
More Related Videos
11:52Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
Published on: June 18, 2013
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Modified-Release Drug Delivery Systems: Site-Targeted
Tumor Immunotherapy